+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2013-05-07Number of Pages: 112

Computational Biology Market (Pharmacodynamics, Cellular Modeling, Computational Genomics, Proteomics, Pharmacogenomics, Pharmacokinetics, Human Simulation Software, Drug Discovery & Development) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018

Global Computational Biology Market: Snapshot

The skyrocketing rates of drugs along with the continuously rising rate of failure of drugs in the late stage of clinical trials are prompting pharma players to shift their focus from traditional methods of clinical trials to predictive models. The increasing demand for predictive models is, therefore, providing a significant boost to the growth of the global computational biology market. Moreover, the increasing funding from governments and private organizations for research and development in this field is propelling the market.

On the other hand, the lack of standardization and dearth of skilled labor is limiting the market from realizing its utmost potential. However, the emergence of cloud computing is likely to shape future of the market. The opportunity in the global computational biology market was worth US$1.64 bn in 2015 and is estimated to rise to US$2.93 bn by the end of 2018, progressing at a phenomenal CAGR of 21.3% from 2012 to 2018.

In-house to Remain Most Valuable Service Segment through 2018

Based on tools, database was the leading segment in terms of revenue in 2015. Their demand is likely to remain strong in the forthcoming years owing to the fact that they serve as the ground for modeling and simulation. However, the analysis software and services segment is expected to outperform database by the end of forecast period. The increasing need for cost-effective software that ensures simplified modeling and simulation is contributing to the growth of the segment. The segment is estimated to rise at a noteworthy CAGR of 25.0% during the forecast period.

On the basis of services, the in-house segment will account for the lion’s share throughout the forecast period, expanding at a 22.6% CAGR during the same period. Current trends in the global market indicate that multinational biotech pharma companies are shifting their own research and development setups in countries with cheap manpower cost such as India, China, and Brazil. This coupled with tax benefits offered by the governments of these nations is anticipated to reduce the cost of conducting in-house research. These factors are, therefore, driving the growth of the segment.

North America to Retain Dominance as Government Organizations Encourage Research and Development Activities

North America will be the frontrunner in the market in terms of revenue throughout the forecast period, with the U.S. being the leading revenue contributor. The growth of the region is supplemented by the conducive environment for the development of bioinformatics and computational biology created by government organizations and continual research and development efforts by pharmaceutical giants. In addition, the U.S. federal government is encouraging the growth of the market through provision of funds for research and development and academic centers using modeling and simulation for drug discovery.

The market for computational biology in Asia Pacific is largely centered in countries such as India, China, and Japan. The presence of a large and trained talent pool of researchers and engineers coupled with robust computational infrastructure is assisting the region in treading along a healthy growth track. Favorable government initiatives and increasing collaborations among international biologists, bioinformatics, and local scientists are augmenting the growth of the region. Owing to these factor, the region is poised to progress at a CAGR of 27.5% during the same period. Some of the prominent players in the global computational biology market are Accelrys, Certara, Chemical Computing Group Inc., Compugen, Entelos, Ltd, Genedata AG, and Insilico Biotechnology AG.

Table of Content
 
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Scope Of The Report
1.4 Research Methodology
      1.4.1 Sources
               1.4.1.1 Secondary Research
               1.4.1.2 Primary Research
               1.4.1.3 Models
1.5 Assumptions
 
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Computational Biology Market (2011 & 2018)
2.2 Global Computational Biology Market, by Types, 2011 (USD Million)
 
Chapter 3 Global Computational Biology Market Dynamics
3.1 Market Overview
3.2 Drivers
      3.2.1 Failure Of Drug Candidates in Late Stage of Clinical Trials
               3.2.1.1 Average Cost to Develop One New Drug (1975 -2011) (USD Million)
               3.2.1.2 Trend of Rise in Failure of Phase II Clinical Trials (2006- 2012)
               3.2.1.3 Reasons For Failure (%) in Phase II & Phase III
      3.2.2 Enhanced Computational Tools
      3.2.3 Improved Government Funding &Industrial Support
3.3 Restraints
      3.3.1 Lack of Standardization
      3.3.2 Non-Verified Predictive Models
3.4 Challenges
      3.4.1 Shortage of Skilled Resources
      3.4.2 Data Storage
3.5 Opportunities
      3.5.1 Cloud Computing
      3.5.2 Modelling And Simulations in Paediatrics Drug Development
3.6 Porters Five Forces Analysis
      3.6.1 Bargaining Power of Suppliers
      3.6.2 Bargaining Power of Buyers
      3.6.3 Threat of New Entrants
      3.6.4 Threat Of Substitutes
      3.6.5 Competitive Rivalry
3.7 Market Attractiveness Analysis
      3.7.1 Market Attractiveness Analysis: Global Computational Biology Market, by Geography
3.8 End User Analysis
      3.8.1 End User Analysis: Global Computational Biology Market, 2011 & 2018 (%)
 
Chapter 4 Global Computational Biology Market, by Applications
4.1 Introduction
      4.1.1 Cellular Modelling and Simulation
               4.1.1.1 Computational Genomics
                          4.1.1.1.1 Global Computational Genomics Market Revenues, 2010 – 2018 (USD Million)
               4.1.1.2 Computational Proteomics
                          4.1.1.2.1 Global Computational Proteomics Market Revenues, 2010 – 2018 (USD Million)
               4.1.1.3 Pharmacogenomics
                          4.1.1.3.1 Global Computational Pharmacogenomics Market Revenues, 2010 – 2018 (USD Million)
               4.1.1.4 Others (Metabolomics/ Transcriptomics)
                          4.1.1.4.1 Global Computational Others (Metabolomics/Transcriptomics) Market Revenue, 2010 – 2018 (USD Million)
      4.1.2 Disease Modelling And Simulation Applications / CADD (Computer Aided Drug Design)
              4.1.2.1 Drug Discovery
                         4.1.2.1.1 Global Computational Drug Discovery Market Revenues, 2010 – 2018 (USD Million)
                         4.1.2.1.2 Target Identification
                                       4.1.2.1.2.1 Global Computational Target Identification Market Revenues, 2010 – 2018 (USD Million)
                         4.1.2.1.3 Target Validation
                                       4.1.2.1.3.1 Global Computational Target Validation Market Revenues, 2010 – 2018 (USD Million)
                         4.1.2.1.4 Lead Identification/Discovery
                                       4.1.2.1.4.1 Global Computational Lead Identification Market Revenues, 2010 – 2018 (USD Million)
                         4.1.2.1.5 Lead Optimization
                                       4.1.2.1.5.1 Global Computational Lead Optimization Market Revenues, 2010 – 2018 (USD Million)
             4.1.2.1 Drug Development
                         4.1.2.1.1 Preclinical
                                       4.1.2.1.1.1 Global Computational Preclinical Trials Market Revenues, 2010 – 2018 (USD Million)
                         4.1.2.1.2 Clinical Trials
                                       4.1.2.1.2.1 Global Computational Clinical Trials Market Revenues, 2010 – 2018 (USD Million)
                                       4.1.2.1.2.2 Phase I
                                       4.1.2.1.2.3 Global Computational Clinical Trials Phase I Market Revenues, 2010 – 2018 (USD Million)
                                       4.1.2.1.2.4 Phase II
                                       4.1.2.1.2.5 Global Computational Clinical Trials Phase II Market Revenues, 2010 – 2018 (USD Million)
                                       4.1.2.1.2.6 Phase III
                                       4.1.2.1.2.7 Global Computational Clinical Trials Phase III Market Revenues, 2010 – 2018 (USD Million)
                         4.1.2.1.3 Human Body Simulation Software
                                       4.1.2.1.3.1 Global Computational Human Simulation Software Market Revenues, 2010 – 2018 (USD Million)
 
Chapter 5 Global Computational Biology Market, by Tools
5.1 Overview
5.2 Database
      5.2.1 Global Computational Biology Database Market Revenues, 2010 – 2018 (USD Million)
5.3 IT Infrastructure (Hardware)
      5.3.1 Global Computational Biology Hardware Market Revenues, 2010 – 2018 (USD Million)
5.4 Analysis Software & Services
      5.4.1 Global Computational Biology Software Market Revenues, 2010 – 2018 (USD Million)
 
Chapter 6 Global Computational Biology Market, by Services
6.1 Overview
6.2 In-House Computational Biology
      6.2.1 Global In-House Computational Biology Market Revenues, 2010 – 2018 (USD Million)
6.3 External/Contract Computational Biology
      6.3.1 Global Contract Computational Biology Market Revenues, 2010 – 2018 (USD Million)
 
Chapter 7 Global Computational Biology Market, by Geography
7.1 Overview
7.2 North America
      7.2.1 North America Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.3 Europe
      7.3.1 Europe Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.4 Asia
      7.4.1 Asia Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.5 ROW
      7.5.1 Row Computational Biology Market Revenues, 2010 – 2018 (USD Million)
 
Chapter 8 Market Share Analysis
8.1 Market Share by Key Players
      8.1.1 Global Computational Biology Market Share Analysis of Key Players, 2011 (%)
 
Chapter 9 Recommendations
9.1 Success Strategies
      9.1.1 Rigorous Research and Development (R&D) Initiatives
      9.1.2 Investing in Emerging Economies
      9.1.3 Investing in High-End Technologies
      9.1.4 Collaborations, Mergers and Acquisitions
9.2 Barriers to be Considered
      9.2.1 High Cost of Investment
 
Chapter 10 Company Profiles
10.1 Accelrys
      10.1.1 Company Overview
      10.1.2 Financial Overview
      10.1.3 Product Portfolio And Services
      10.1.4 Business Strategy
      10.1.5 Recent Developments
10.2 Certara
      10.2.1 Company Profile
      10.2.2 Financial Overview
      10.2.3 Product Portfolio And Services
      10.2.4 Business Strategy
      10.2.5 Recent Developments
10.3 Chemical Computing Group Inc.
      10.3.1 Company Profile
      10.3.2 Financial Overview
      10.3.3 Product Portfolio
      10.3.4 Business Strategy
      10.3.5 Recent Developments
10.4 Compugen, Ltd
      10.4.1 Company Profile
      10.4.2 Financial Overview
      10.4.3 Business Strategy
      10.4.4 Recent Developments
10.5 Entelos
      10.5.1 Company Profile
      10.5.2 Financial Overview
      10.5.3 Product Portfolio And Services
      10.5.4 Business Strategy
      10.5.5 Recent Developments
10.6 Genedata AG
      10.6.1 Company Profile
      10.6.2 Financial Overview
      10.6.3 Product Portfolio And Services
      10.6.4 Business Strategy
      10.6.5 Recent Developments
10.7 Insilico Biotechnology AG
      10.7.1 Company Profile
      10.7.2 Financial Overview
      10.7.3 Product Portfolio
      10.7.4 Business Strategy
      10.7.5 Recent Developments
10.8 Leadscope, Inc
      10.8.1 Company Profile
      10.8.2 Financial  Overview
      10.8.3 Product Portfolio
      10.8.4 Business Strategy
      10.8.5 Recent Developments
10.9 Nimbus Discovery LLC
      10.9.1 Company Profile
      10.9.2 Financial Overview
      10.9.3 Product Portfolio
      10.9.4 Business Strategy
      10.9.5 Recent Developments
10.10 Rhenovia  Pharma SAS
      10.10.1 Company Profile
      10.10.2 Financial Overview
      10.10.3 Product Portfolio And Services
      10.10.4 Business Startegy
      10.10.5 Recent Developments
10.11 Schrodinger
      10.11.1 Company Overview
      10.11.2 Financial Overview
      10.11.3 Product Portfolio And Services
      10.11.4 Business Strategy
      10.11.5 Recent Developments
10.12 Simulation Plus, Inc.
      10.12.1 Company Profile
      10.12.2 Financial Overview
      10.12.3 Product Portfolio And Services
      10.12.4 Business Strategy
      10.12.5 Recent Developments

List of Figures
 
FIG. 1 Global Computational Biology: Market Segmentation
FIG. 2 Global Computational Biology Market, By Types, 2011 (USD Million)
FIG. 3 Average Cost to Develop one New Drug (1975 -2011) (USD Million)
FIG. 4 Trend of Rise in Failure of Phase II Clinical Trials (2006- 2012)
FIG. 5 Reasons for Failure (%) in Phase II & Phase III
FIG. 6 Porter’s Five Forces Analysis for Computational Biology Market
FIG. 7 Market Attractiveness Analysis: Global Computational Biology Market, By Geography
FIG. 8 End User Analysis: Global Computational Biology Market, 2011 & 2018 (%)
FIG. 9 Global Computational Genomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 10 Global Computational Proteomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 11 Global Computational Pharmacogenomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 12 Global Computational Others (Metabolomics/ Transcriptomics) Market Revenue, 2010 – 2018 (USD Million)
FIG. 13 Global Computational Drug Discovery Market Revenues, 2010 – 2018 (USD Million)
FIG. 14 Global Computational Target Identification Market Revenues, 2010 – 2018 (USD Million)
FIG. 15 Global Computational Target Validation Market Revenues, 2010 – 2018 (USD Million)
FIG. 16 Global Computational Lead Identification Market Revenues, 2010 – 2018 (USD Million)
FIG. 17 Global Computational Lead Optimization Market Revenues, 2010 – 2018 (USD Million)
FIG. 18 Global Computational Preclinical Trials Market Revenues, 2010 – 2018 (USD Million)
FIG. 19 Global Computational Clinical Trials Market Revenues, 2010 – 2018 (USD Million)
FIG. 20 Global Computational Clinical Trials Phase I Market Revenues, 2010 – 2018 (USD Million)
FIG. 21 Global Computational Clinical Trials Phase II Market Revenues, 2010 – 2018 (USD Million)
FIG. 22 Global Computational Clinical Trials Phase III Market Revenues, 2010 – 2018 (USD Million)
FIG. 23 Global Computational Human Simulation Software Market Revenues, 2010 – 2012 (USD Million)
FIG. 24 Global Computational Biology Database Market Revenues, 2010 – 2018 (USD Million)
FIG. 25 Global Computational Biology Hardware Market Revenues, 2010 – 2018 (USD Million)
FIG. 26 Global Computational Biology Software Market Revenues, 2010 – 2018 (USD Million)
FIG. 27 Global In-House Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 28 Global Contract Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 29 North America Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 30 Europe Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 31 Asia Computational Biology Market Revenue, 2010 – 2018 (USD Million)
FIG. 32 Row Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 33 Global Computational Biology Market Share Analysis Of Key Players, 2011 (%)
FIG. 34 Annual Revenues: Accelrys, 2009 - 2011 (USD Million)
FIG. 35 Annual Revenue: Compugen, 2010 – 2012 (USD Million)
FIG. 36 Annual Revenues: Simulation Plus, Inc., 2010 – 2012 (USD Million)

List of Tables
 
TABLE 1 Global Computational Biology Market: Snapshot (2011 & 2018)
TABLE 2 R&D Function by Expenditure (%)
TABLE 3 Global Computational Biology Market Revenues, by Segments, 2010 – 2018 (USD Million)
TABLE 4 Global Cellular Modeling and Biology Simulation Market Revenues, by Types, 2010 – 2018 (USD Million)
TABLE 5 Global Cellular Modeling and Biology Simulation Market Revenues, by Geography, 2010 – 2018 (USD Million)
TABLE 6 Global Disease Modeling and Simulation Market Revenues, by Types, 2010 - 2018 (USD Million)
TABLE 7 Global Disease Modeling and Simulation Market Revenues, by Geography, 2010 - 2018 (USD Million)
TABLE 8 Global Computational Drug Development Market Revenues, by Types, 2010 - 2018 (USD Million)
TABLE 9 Software Packages for PBPK Modeling
TABLE 10 Global Computational Biology Market Revenues, by Tools, 2010- 2018 (USD Million)
TABLE 11 Global Computational Services Market Revenues, by Services, 2010- 2018 (USD Million)
TABLE 12 Global Computational Biology Market, by Geography, 2010- 2018 (USD Million)

 
The computational biology market is predicted to have a notable growth owing to its wide use by biotechnology and pharmaceutical companies to reduce the incidences of late stage failures of their drugs and thereby curb R&D expenditure. This market involves application of biology and information technology field for drug discovery and drug development. Computational biology also assists in reducing extensive use of human in clinical trials and is therefore useful for pediatric trials, trials on pregnant women and orphan disease research. The computational biology market has witnessed significant growth in the past due to rise in late stage drug failure coupled with its ability to reduce extensive use of humans in clinical trials. 
 
This report provides an in-depth and comprehensive analysis of the computational biology market on the basis of application, tools and by services. This report studies the global market for computational biology through the perspective of cellular modeling and disease modeling. In application segment, the report covers cellular & biological simulation and disease modeling and simulation application or CADD (Computer Aided Drug Design). Cellular & biological simulation market has also been segmented on the basis of computational genomics, computational proteomics, pharmacogenomics and others (transcriptomics/ metabolomics). Disease modeling and simulation segment is categorized into drug discovery and drug development. The market of drug discovery is divided into target identification, target validation, lead discovery and lead optimization. Drug development market is segmented as preclinical, clinical trials and human body simulation software. The market of clinical trials is studies based on phase I, phase II and phase III trials. 
 
The market of computational biology market, by tools is categorized into database, IT infrastructure (hardware) and analysis software and services types. The computational biology services market highlights the trend of in-house computational biology and external or contract computational biology. The report also provides various types of technological advancements taking place in each segment. All the above mentioned segments are analyzed on the basis of market size in terms of USD million and their forecasts for the period 2012 to 2018 have also been provided. The CAGR (%) for each market segment has been estimated for the forecast period 2012 to 2018, considering 2011 as the base year. In addition, this report covers participation of different organizations of the U.S. and the U.K. for the development of computational biology market.
 
The market is also forecasted in terms of value (USD million) for the period 2012 – 2018 for four major geographic regions, namely North America, Europe, Asia-Pacific and Rest of the World (RoW). Market sizes, forecasts and % CAGR for each region have been provided in geography segment. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the computational biology market and future opportunities are covered in the report. Moreover, a PESTLE analysis has been done while estimating individual geographies in order to provide current as well as future status. A list of recommendations for existing as well as new entrants has been discussed in the study. This recommendation chapter provides assistance to industry players on ways to enter this market or to establish sustainable competitive advantage.
 
Some of the key market players of the global computational biology market include Genedata AG, Nimbus Discovery LLC, Rhenovia Pharma SAS, Certara, Chemical Computing Group, Inc., Compugen, Ltd,  Simulation Plus, Inc., Schrodinger, Leadscope, Inc., Accelrys, Entelos and Insilico Biotechnology AG. Market players are profiled in this report on the basis of attributes such as company overview, financial overview, business strategies adopted by the companies to ensure sustainability and maximize profits, product portfolio and recent developments. The competitive landscape of this industry has been covered under market share analysis by key players.


 
 
Back To Top